Yesterday, OMB Watch submitted comments on FDA's proposed conflict of interest guidelines for agency scientific advisory panels. Avoiding conflicts of interest on these panels is important to ensuring scientific integrity, responsible use of agency resources, and strong final regulatory actions. OMB Watch complements some provisions in the proposed guidance, but also encourages FDA to close certain loopholes which undermine its intent. As stated in the comments, "OMB Watch is concerned the draft guidance creates loopholes and does not reflect the spirit of impartiality in regard to the identification of the need for a unique individual to serve on an agency advisory committee." Click here to read OMB Watch's comments. Click here to read OMB Watch's detailed analysis of the proposed guidance.